BUCCOLAM 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
N/0060 
Minor change in labelling or package leaflet not 
17/01/2024 
PL 
connected with the SPC (Art. 61.3 Notification) 
PSUSA/10118
Periodic Safety Update EU Single assessment - 
26/04/2023 
07/07/2023 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
/202209 
midazolam (oromucosal solution, treatment of 
the variation to terms of the Marketing Authorisation(s)’ for 
prolonged, acute, convulsive seizures) 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
IAIN/0059/G 
This was an application for a group of variations. 
21/06/2023 
A.5.a - Administrative change - Change in the name 
and/or address of a manufacturer/importer 
responsible for batch release 
A.1 - Administrative change - Change in the name 
and/or address of the MAH 
A.7 - Administrative change - Deletion of 
manufacturing sites 
PSUSA/10118/202209. 
SmPC, Annex 
II, Labelling 
and PL 
N/0058 
Minor change in labelling or package leaflet not 
08/02/2023 
07/07/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0056 
C.I.z - Changes (Safety/Efficacy) of Human and 
31/10/2022 
07/07/2023 
SmPC and PL 
To update section 4.4 of the SmPC and section 2 of the PL 
Veterinary Medicinal Products - Other variation 
to align the wording for the excipient sodium with the 
European Commission guideline on ‘Excipients in the 
labelling and package leaflet of medicinal products for 
human use’ (EMA/CHMP/302620/2017 Rev. 1*). 
IA/0055 
B.II.b.2.a - Change to importer, batch release 
12/04/2022 
n/a 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
IAIN/0054 
B.II.e.6.a - Change in any part of the (primary) 
10/02/2022 
13/05/2022 
SmPC, 
packaging material not in contact with the finished 
product formulation - Change that affects the 
product information 
Labelling and 
PL 
IAIN/0053/G 
This was an application for a group of variations. 
18/11/2021 
13/05/2022 
Annex II and 
Page 2/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PL 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
IA/0052 
B.III.1.a.2 - Submission of a new/updated or 
21/09/2021 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IB/0051/G 
This was an application for a group of variations. 
07/07/2021 
13/05/2022 
SmPC, 
The Product Information was updated to add the additional 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
Labelling and 
pack size of two pre-filled syringes for each of the four 
PL 
strengths. 
Page 3/13 
 
 
 
 
 
 
 
 
 
 
 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
IAIN/0050 
B.II.b.1.a - Replacement or addition of a 
26/05/2021 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IAIN/0049 
B.II.b.2.c.1 - Change to importer, batch release 
09/04/2021 
13/05/2022 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
T/0048 
Transfer of Marketing Authorisation 
22/12/2020 
25/02/2021 
SmPC, 
Labelling and 
PL 
IB/0047 
C.I.11.z - Introduction of, or change(s) to, the 
21/01/2021 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IAIN/0046 
B.II.b.2.c.1 - Change to importer, batch release 
22/10/2020 
n/a 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IB/0045 
C.I.3.a - Change(s) in the SPC, Labelling or PL 
16/10/2020 
25/02/2021 
SmPC 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Implementation of 
wording agreed by the competent authority 
Page 4/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/10118
Periodic Safety Update EU Single assessment - 
28/05/2020 
27/07/2020 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
/201909 
midazolam (oromucosal solution, treatment of 
the variation to terms of the Marketing Authorisation(s)’ for 
prolonged, acute, convulsive seizures) 
PSUSA/10118/201909. 
IA/0044/G 
This was an application for a group of variations. 
22/06/2020 
n/a 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
IAIN/0042/G 
This was an application for a group of variations. 
30/10/2019 
n/a 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
Page 5/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
responsible for importation and/or batch release - 
Not including batch control/testing 
IB/0041/G 
This was an application for a group of variations. 
20/10/2019 
27/07/2020 
SmPC and 
Labelling 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure 
(including replacement or addition) 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
life of the finished product - As packaged for sale 
(supported by real time data) 
IA/0039 
B.II.b.2.a - Change to importer, batch release 
03/08/2018 
n/a 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
N/0038 
Minor change in labelling or package leaflet not 
25/07/2018 
12/02/2019 
Labelling 
connected with the SPC (Art. 61.3 Notification) 
IB/0037 
B.II.b.5.f - Change to in-process tests or limits 
24/05/2018 
n/a 
applied during the manufacture of the finished 
product - Addition or replacement of an in-process 
test as a result of a safety or quality issue 
IAIN/0036 
B.II.b.2.c.1 - Change to importer, batch release 
02/02/2018 
12/02/2019 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
Page 6/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/10118
Periodic Safety Update EU Single assessment - 
06/04/2017 
n/a 
PRAC Recommendation - maintenance 
/201609 
midazolam (oromucosal solution, treatment of 
prolonged, acute, convulsive seizures) 
R/0032 
Renewal of the marketing authorisation. 
01/04/2016 
26/05/2016 
SmPC, Annex 
II, Labelling 
and PL 
IA/0033 
A.5.b - Administrative change - Change in the name 
02/05/2016 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
PSUSA/10118
Periodic Safety Update EU Single assessment - 
17/03/2016 
n/a 
PRAC Recommendation - maintenance 
/201509 
midazolam (oromucosal solution, treatment of 
prolonged, acute, convulsive seizures) 
IG/0603/G 
This was an application for a group of variations. 
03/12/2015 
26/05/2016 
SmPC, Annex 
A.1 - Administrative change - Change in the name 
and/or address of the MAH 
A.5.a - Administrative change - Change in the name 
and/or address of a manufacturer/importer 
responsible for batch release 
II, Labelling 
and PL 
IG/0621 
C.I.8.a - Introduction of or changes to a summary of 
16/10/2015 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
IA/0028 
B.II.b.3.a - Change in the manufacturing process of 
09/10/2015 
n/a 
the finished or intermediate product - Minor change 
Page 7/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
in the manufacturing process 
IA/0027 
B.II.b.2.a - Change to importer, batch release 
16/07/2015 
n/a 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
PSUSA/10118
Periodic Safety Update EU Single assessment - 
12/03/2015 
n/a 
PRAC Recommendation - maintenance 
/201409 
midazolam (oromucosal solution, treatment of 
prolonged, acute, convulsive seizures) 
IB/0025/G 
This was an application for a group of variations. 
29/10/2014 
n/a 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
A.7 - Administrative change - Deletion of 
manufacturing sites 
IA/0024 
B.II.b.3.a - Change in the manufacturing process of 
26/09/2014 
n/a 
the finished or intermediate product - Minor change 
in the manufacturing process 
IAIN/0023 
C.I.8.a - Introduction of or changes to a summary of 
02/07/2014 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
PSUV/0012 
Periodic Safety Update 
10/04/2014 
n/a 
PRAC Recommendation - maintenance 
Page 8/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0020 
B.II.b.1.e - Replacement or addition of a 
28/03/2014 
n/a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch-
release, batch control, primary and secondary 
packaging, for non-sterile medicinal products 
IB/0021/G 
This was an application for a group of variations. 
26/03/2014 
n/a 
B.II.e.2.c - Change in the specification parameters 
and/or limits of the immediate packaging of the 
finished product - Deletion of a non-significant 
specification parameter (e.g. deletion of an obsolete 
parameter) 
B.II.e.2.z - Change in the specification parameters 
and/or limits of the immediate packaging of the 
finished product - Other variation 
IB/0019 
Update of section 6.6 of the SmPC to include 
20/03/2014 
05/03/2015 
SmPC, Annex 
information on how to administer Buccolam as 
already introduced in the Package Leaflet. In addition 
several editorial corrections including an update of 
the entire PI in accordance with QRD template 
version 9 have also been introduced. 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
II, Labelling 
and PL 
IA/0022 
A.7 - Administrative change - Deletion of 
27/02/2014 
05/03/2015 
Annex II and 
manufacturing sites 
PL 
IAIN/0018 
B.II.b.1.b - Replacement or addition of a 
17/02/2014 
n/a 
Page 9/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
manufacturing site for the FP - Primary packaging 
site 
IAIN/0016/G 
This was an application for a group of variations. 
17/02/2014 
n/a 
C.I.9.a - Changes to an existing pharmacovigilance 
system as described in the DDPS - Change in the 
QPPV and/or QPPV contact details and/or back-up 
procedure 
C.I.9.b - Changes to an existing pharmacovigilance 
system as described in the DDPS - Change(s) in the 
safety database and/or major contractual 
arrangements for the fulfilment of PhV obligations, 
and/or change of the site undergoing PhV activities 
C.I.9.c - Changes to an existing pharmacovigilance 
system as described in the DDPS - Other change(s) 
to the DDPS that does not impact on the operation of 
the PhV system 
IA/0017 
B.II.b.3.a - Change in the manufacturing process of 
12/02/2014 
n/a 
the finished or intermediate product - Minor change 
in the manufacturing process 
IB/0015 
B.II.e.1.z - Change in immediate packaging of the 
11/02/2014 
n/a 
finished product - Other variation 
IB/0014 
B.II.b.4.z - Change in the batch size (including batch 
31/01/2014 
n/a 
size ranges) of the finished product - Other variation 
N/0011 
Minor change in labelling or package leaflet not 
17/01/2014 
05/03/2015 
Labelling and 
The MAH applied for the introduction of a wrap-around tube 
connected with the SPC (Art. 61.3 Notification) 
PL 
label with improved visual images and a multi-strength 
Page 10/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0013 
B.II.b.4.a - Change in the batch size (including batch 
19/12/2013 
n/a 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
IB/0008 
B.II.b.5.b - Change to in-process tests or limits 
07/11/2013 
n/a 
applied during the manufacture of the finished 
product - Addition of a new test(s) and limits 
IAIN/0010 
B.II.b.1.a - Replacement or addition of a 
06/11/2013 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IAIN/0009 
B.II.b.1.a - Replacement or addition of a 
24/10/2013 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IA/0007/G 
This was an application for a group of variations. 
14/08/2013 
n/a 
B.III.1.a.2 - Submission of a new or updated Ph. Eur. 
Certificate of Suitability to the relevant Ph. Eur. 
Monograph - Updated certificate from an already 
approved manufacturer 
B.III.1.a.2 - Submission of a new or updated Ph. Eur. 
Certificate of Suitability to the relevant Ph. Eur. 
Monograph - Updated certificate from an already 
approved manufacturer 
Package Leaflet with the introduction of colour to 
differentiate between the strengths for optimum clarity. 
The labelling and PL have been updated accordingly. 
Page 11/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0006 
B.III.1.a.2 - Submission of a new or updated Ph. Eur. 
17/06/2013 
n/a 
Certificate of Suitability to the relevant Ph. Eur. 
Monograph - Updated certificate from an already 
approved manufacturer 
IAIN/0005/G 
This was an application for a group of variations. 
02/05/2013 
n/a 
C.I.9.a - Changes to an existing pharmacovigilance 
system as described in the DDPS - Change in the 
QPPV 
C.I.9.c - Changes to an existing pharmacovigilance 
system as described in the DDPS - Change of the 
back-up procedure of the QPPV 
C.I.9.e - Changes to an existing pharmacovigilance 
system as described in the DDPS - Changes in the 
major contractual arrangements with other persons 
or organisations involved in the fulfilment of 
pharmacovigilance obligations and described in the 
DD 
C.I.9.h - Changes to an existing pharmacovigilance 
system as described in the DDPS - Other change(s) 
to the DDPS that does not impact on the operation of 
the pharmacovigilance system 
IAIN/0004/G 
This was an application for a group of variations. 
13/12/2012 
18/12/2013 
SmPC, Annex 
II and PL 
A.6 - Administrative change - Change in ATC 
Code/ATC Vet Code 
B.II.b.2.b.1 - Change to batch release arrangements 
and quality control testing of the FP - Not including 
batch control/testing 
Page 12/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0003/G 
This was an application for a group of variations. 
22/08/2012 
n/a 
C.I.9.e - Changes to an existing pharmacovigilance 
system as described in the DDPS - Changes in the 
major contractual arrangements with other persons 
or organisations involved in the fulfilment of 
pharmacovigilance obligations and described in the 
DD 
C.I.9.h - Changes to an existing pharmacovigilance 
system as described in the DDPS - Other change(s) 
to the DDPS that does not impact on the operation of 
the pharmacovigilance system 
IB/0002 
B.II.b.5.a - Change to in-process tests or limits 
16/08/2012 
n/a 
applied during the manufacture of the finished 
product - Tightening of in-process limits 
IB/0001 
B.II.e.2.b - Change in the specification parameters 
16/12/2011 
n/a 
and/or limits of the immediate packaging of the 
finished product - Addition of a new specification 
parameter to the specification with its corresponding 
test method 
Page 13/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
